28 completed, 11 active not recruiting, 8 recruiting, 8 unknown. 26 Phase 2, 19 Phase 1, 9 Not applicable, 1 Phase 3.
Follow this condition Literature Review of Chordoma trials Research Report on Chordoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Genetics Branch Eligibility Screening Survey Melanoma, Li-Fraumeni Syndrome | Not yet recruiting | National Cancer Institute (NCI) | 1000 | 2026-10-26 | 2026-10-21 | |
| China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm Tumor resection followed by aneurysm treatment, Aneurysm treatment followed by tumor resection, Observation - Unruptured Intracranial Aneurysms, Pituitary Neuroendocrine Tumor | Active not recruiting | Cheng sen | 608 | 2026-10-20 | 2026-10-21 | |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE Questionnaire - Cancer, Cystic Carcinomas, Adenoid | Completed | Hospices Civils de Lyon | 62 | 2025-05-23 | 2025-08-06 | |
| A Study of ERAS-601 in People With Chordoma ERAS-601 - Chordoma | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 12 | 2025-04-25 | 2026-04-28 |
| A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma BL-B01D1 - Chordoma | Phase 2 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 27 | 2025-01-16 | 2026-04-13 |
| Pembrolizumab and Pemetrexed for Progressive Chordoma Pembrolizumab, Pemetrexed Phase 2 - Chordomas, Chordoma | Phase 2 | Recruiting | Saint John's Cancer Institute | 21 | 2025-01-01 | 2025-01-27 |
| Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma camrelizumab and apatinib - Chordoma, Chemotherapy Effect | Phase 2 | Unknown | Xuanwu Hospital, Beijing | 30 | 2023-10-30 | 2023-11-20 |
| Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy Proteus ONE one daily beam, Proteus ONE two daily beam - Chordoma, Chondrosarcoma | Not applicable | Recruiting | Centre Antoine Lacassagne | 106 | 2023-09-13 | 2024-09-25 |
| Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors Tazemetostat, Nivolumab, Ipilimumab - Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors | Phase 1 / Phase 2 | Active not recruiting | Susan Chi, MD | 49 | 2023-08-10 | 2026-04-13 |
| Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base 5-fraction hipofractionated protontheray, 25-fraction hypofractionated proton therapy - Chordoma, Chondrosarcoma | Not applicable | Recruiting | Quironsalud | 20 | 2023-05-24 | 2026-01-23 |
| A Prospective Study of Surgical Treatment Strategies for Chordoma Resection surgery - Chordoma of Spine, Surgery | Not applicable | Unknown | Xuanwu Hospital, Beijing | 100 | 2023-02-01 | 2023-07-19 |
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Atezolizumab, Biospecimen Collection, Computed Tomography - Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-11-17 | 2026-07-14 |
| Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma Cetuximab, Questionnaire Administration - Chordoma, Metastatic Chordoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 29 | 2022-05-27 | 2026-09-04 |
| A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors CFT8634 - Synovial Sarcoma, Soft Tissue Sarcoma | Phase 1 | Terminated | C4 Therapeutics, Inc. | 49 | 2022-03-25 | 2024-12-17 |
| Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone Electronic Health Record Review, Quality-of-Life Assessment - Bone Sarcoma, Chondrosarcoma | Recruiting | Mayo Clinic | 72 | 2022-01-20 | 2026-03-13 | |
| Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas Bone Neoplasm of Vertebral Column, Chordoma | Recruiting | Leiden University Medical Center | 40 | 2021-02-02 | 2023-11-18 | |
| A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors ERAS-601, Cetuximab, Pembrolizumab - Advanced or Metastatic Solid Tumors | Phase 1 | Completed | Erasca, Inc. | 90 | 2020-12-15 | 2026-09-16 |
| Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers Nivolumab, Ipilimumab - Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 30 | 2020-08-14 | 2026-10-20 |
| TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer TAEK-VAC-HerBy - Chordoma, HER2-positive Breast Cancer | Phase 1 | Completed | Bavarian Nordic | 37 | 2020-08-10 | 2025-03-03 |
Showing 20 of 62. Sign in to see all of them.
Sarcoma (16) · Chondrosarcoma (13) · Neoplasms (7) · Osteosarcoma (7) · Sarcoma, Ewing (7) · Meningioma (6) · Desmoid Tumors (5) · Rhabdoid Tumor (5) · Astrocytoma (4) · Carcinoma, Adenoid Cystic (4) · Craniopharyngioma (4) · Desmoplastic Small Round Cell Tumor (4) · Hemangiosarcoma (4) · Neurofibrosarcoma (4)
Neoplasms by Histologic Type (62) · Neoplasms, Germ Cell and Embryonal (60) · Neoplasms (55) · Neoplasms, Connective and Soft Tissue (28) · Neoplasms, Connective Tissue (23) · Neoplasms by Site (19) · Neoplasms, Nerve Tissue (15) · Neoplasms, Glandular and Epithelial (12) · Nervous System Diseases (12) · Nervous System Neoplasms (12) · Neuroectodermal Tumors (12) · Sarcoma (12) · Neoplasms, Bone Tissue (11) · Neoplasms, Vascular Tissue (11) · Neoplasms, Complex and Mixed (9)
Nivolumab (6) · Imatinib Mesylate (4) · Cetuximab (3) · Ipilimumab (3) · Cyclophosphamide (2) · Magnetic Resonance Spectroscopy (2) · Pemetrexed (2) · Proton Therapy (2) · Protons (2) · Radiosurgery (2) · Radiotherapy (2) · Specimen Handling (2) · palbociclib (2) · pembrolizumab (2) · ALT-803 (1)
National Cancer Institute (NCI) (6) · Massachusetts General Hospital (3) · Novartis Pharmaceuticals (3) · Bavarian Nordic (2) · Children's Oncology Group (2) · Harry T Whelan, MD (2) · Heidelberg University (2) · Leiden University Medical Center (2) · M.D. Anderson Cancer Center (2) · Saint John's Cancer Institute (2) · University of Florida (2) · Xuanwu Hospital, Beijing (2) · Abramson Cancer Center at Penn Medicine (1) · Aveni Foundation (1) · BioMed Valley Discoveries, Inc (1)
United States (41) · China (5) · France (5) · Germany (4) · Italy (4) · Netherlands (4) · Spain (4) · United Kingdom (4) · Australia (3) · Canada (3) · Ireland (2) · Japan (2) · Switzerland (2) · Austria (1) · Guam (1)
Harry T Whelan, MD (2) · AJ Gelderblom, Prof (1) · Alessandro Gronchi, MD (1) · Alisa M Goldstein, Ph.D. (1) · Anna Estival (1) · Anthony P Conley, MD (1) · Antonio Casado (1) · Arun Singh (1) · Beatrice Seddon, Ph.D., M.D (1) · Bethany Sleckman, MD (1) · Bradford S. Hoppe, MD, MPH (1)
PMID 34266694, PMID 18728566, PMID 19451433, PMID 20572041, PMID 21054824, PMID 22300861, PMID 22752346, PMID 23744869, PMID 23845268, PMID 24089446, PMID 31243811, PMID 31401903, PMID 31902458, PMID 31969335, PMID 33046513, PMID 33362722, PMID 33567141, PMID 33882143, PMID 34380663, PMID 34716198, PMID 37147496, PMID 37429302, PMID 38243705, PMID 38358334, PMID 38501690, PMID 38875730, PMID 39067873, PMID 39122389, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39649870, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41414803, PMID 41672597, PMID 41793771, PMID 41892875, PMID 41995270, PMID 42499790
2008 (1), 2016 (1), P30CA006973 (1), U10CA024507 (1), U10CA180888 (1), UG1CA189958 (1), UM1CA228823 (1)